$27.56
+0.16 (+0.58%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IMNM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 9 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, MARSHALL WACE, LLP, Qube Research & Technologies Ltd, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, +4 more) · FINRA short interest 23.0 days to cover (settled 2026-07-31) · insider 90d: 3 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced CancerNCT07505771Safety and tolerability of 177Lu-IM-3050 in participants with advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Early Phase 1 | Recruiting | Drug: 177Lu-IM-3050 | Solid Malignancies | 105 | Dec 2029 | ≤ 1,230 d | 2026-07-29 |
| A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: IM-1617 | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 175 | Jan 2029 | ≤ 896 d | 2026-07-09 |
| A Phase 1 Study of IM-1021 in Participants With Advanced CancerNCT06823167Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: IM-1021 | Solid Malignancies, Hematologic Malignancies | 190 | May 2028 | ≤ 651 d | 2026-08-10 |
| A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy ParticipantsNCT07610005Evaluate the rBA of varegacestat by AUC0-tRandomized · Open-label · Other | Phase 1 | Recruiting | Drug: Varegacestat Reference Formulation, Varegacestat Test Formulation | Healthy | 20 | Jun 2026 | — | 2026-06-08 |
| A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282Part A: Safety and Tolerability - Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: AL102 · Other: Placebo | Desmoid, Desmoid Tumor | 198 | 2025-12-03actual | — | 2026-06-08 |
| A Varegacestat Hepatic Impairment StudyNCT06841315PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Open-label · Other | Phase 1 | Completed | Drug: varegacestat | Healthy Volunteer, Hepatic Impairment (HI) | 35 | 2025-11-05actual | — | 2026-03-10 |
| A Cardiac Liability Study of Varegacestat in Healthy ParticipantsNCT06855264Placebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrationsRandomized · Double-masked · Other | Phase 1 | Completed | Drug: varegacestat, Placebo, Moxifloxacin 400 mg | Healthy Volunteer | 32 | 2025-04-08actual | — | 2025-09-24 |
| A Phase 1 Mass Balance Study of VaregacestatNCT06845852The mass balance of varegacestat following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.Open-label · Other | Phase 1 | Completed | Drug: varegacestat | Healthy Volunteer | 6 | 2025-03-11actual | — | 2025-09-26 |
| A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy ParticipantsNCT06677996Effect of itraconazole on the PK of varegacestat in healthy participants.Open-label · Other | Phase 1 | Completed | Drug: varegacestat, Itraconazole (200 mg) | Healthy Volunteer | 22 | 2024-12-30actual | — | 2025-05-11 |
| IMM-BCP-01 in Mild to Moderate COVID-19NCT05429021Incidence and severity of Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision to discontinue the study based on strategic prioritization. | Drug: IMM-BCP-01, Placebo | SARS-CoV2 Infection, COVID-19 | 9 | 2023-01-06actual | — | 2024-09-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19